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Background: We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 
(DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin (HbA1c) in patients 
with type 2 diabetes mellitus (T2DM).
Methods: This was a single-arm, multicenter, 24-week, open-label, phase 4 study in patients with inadequately controlled (HbA1c 
≥7.5%) T2DM despite the use of DPP-4 inhibitor and metformin. A total of 108 patients received insulin glargine while continu-
ing oral antidiabetic drugs (OADs). The primary efficacy endpoint was the percentage of subjects achieving HbA1c ≤7.0%. Other 
glycemic profiles were also evaluated, and the safety endpoints were adverse events (AEs) and hypoglycemia.
Results: The median HbA1c at baseline (8.9%; range, 7.5% to 11.1%) decreased to 7.6% (5.5% to 11.7%) at 24 weeks. Overall, 
31.7% subjects (n=33) achieved the target HbA1c level of ≤7.0%. The mean differences in body weight and fasting plasma glu-
cose were 1.2±3.4 kg and 56.0±49.8 mg/dL, respectively. Hypoglycemia was reported in 36 subjects (33.3%, 112 episodes), all of 
which were fully recovered. There was no serious AE attributed to insulin glargine. Body weight change was significantly different 
between SU users and nonusers (1.5±2.5 kg vs. –0.9±6.0 kg, P=0.011).
Conclusion: The combination add-on therapy of insulin glargine, on metformin and DPP-4 inhibitors with or without SU was 
safe and efficient in reducing HbA1c levels and thus, is a preferable option in managing T2DM patients exhibiting dysglycemia 
despite the use of OADs.
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INTRODUCTION
Patients with longstanding type 2 diabetes mellitus (T2DM) 
exhibit progressive β-cell dysfunction [1], and the impaired in-
sulin secretion challenges the maintenance of the glycemic 
profile within the recommended glycosylated hemoglobin 
(HbA1c) goal of ≤7%, as suggested by the American Diabetes 
Association; hence, adjustment of therapy is often advised in 
these patients [2]. 
Theoretically, therapies overcoming the decline in pancreatic 
β-cell function without causing much weight gain and hypo-
glycemic episodes are desirable [3]. In these regards, dipeptidyl 
peptidase 4 (DPP-4) inhibitors have emerged as a promising 
class of antidiabetic agents for the treatment of insulinopenic 
T2DM patients, because they exert protective roles on pancre-
atic β-cells while inhibiting glucagon secretion by α-cells [4], 
and also because they target multiple extrapancreatic organs 
via incretin-related mechanisms [5]. In reality, however, use of 
DPP-4 inhibitors achieves the HbA1c goal in only approxi-
mately 40% of patients [3], thereby leaving insulin the main-
stay of treatment in T2DM patients with insulinopenia.
Although the effectiveness of insulin therapy has been well 
established by various clinical studies, its use is associated with 
risks of hypoglycemia and weight gain [6]. DPP-4 inhibitors 
and insulin exert their antidiabetic effects via different mecha-
nisms, and their complementary effects therefore make the 
combination of these two agents a logical treatment option [7]. 
This combination might enable tighter glycemic control with a 
relatively low risk of hypoglycemia, because the basal insulin 
would theoretically supplement endogenous insulin produc-
tion and alleviate the load on β-cells, facilitating recovery of 
the endogenous insulin response when it is required [8]. In 
fact, several clinical trials have demonstrated the value of add-
ing DPP-4 inhibitors to the treatment regimen of T2DM pa-
tients already receiving insulin treatment [9-12]. In these trials, 
an additional reduction in HbA1c levels of 0.5% to 0.6% was 
achieved without an apparent weight gain or an increase in the 
incidence of hypoglycemia, implying that this combination is 
both efficacious and safe [9-12]. However, all of these trials 
were designed to determine the effect of adding DPP-4 inhibi-
tors to the treatment regimen of patients using insulin. Re-
search into the effects of adding insulin in insulin-free subjects 
who are already taking DPP-4 inhibitors or other oral antidia-
betic drugs (OADs) has been limited [8].
Insulin glargine is an analogue of human insulin that has 
been modified to provide a consistent level of plasma insulin 
over a long period, thereby resulting in a relatively lower rate of 
weight gain and incidence of hypoglycemia [13]. However, to 
date, the effect of adding insulin glargine to DPP-4 inhibitors 
and other OADs has not been evaluated. Thus, in this study, we 
aimed to investigate the effectiveness and safety of adding in-
sulin glargine to DPP-4 inhibitors and metformin and/or sul-
fonylureas (SUs) in achieving the target HbA1c in T2DM pa-
tients.
METHODS
Patients and trial design
This study was a phase 4, multicenter, open-label, single-arm 
study. Study participants were recruited from 11 university 
hospitals throughout Korea (Clinical Trials.gov number, NCT-
02027753). Participants who gave written informed consent 
were screened using inclusion and exclusion criteria. Men and 
women aged ≥20 years with inadequately controlled T2DM 
(i.e., HbA1c ≥7.5%) despite a combination therapy of a DPP-4 
inhibitor and metformin±SU for at least 3 months were eligi-
ble for this study. 
Major exclusion criteria included the following: diabetes 
other than T2DM; history of continuous basal insulin admin-
istration within the preceding 1 year; history of diabetic keto-
acidosis within 1 year; history of admission for myocardial in-
farction, stroke, or heart failure within the preceding 3 months; 
history of drug or alcohol abuse within the preceding 6 months; 
body weight (BW) change ≥5 kg within the preceding 3 months; 
history of hypoglycemic unawareness; medication history of 
drugs that can influence of glucose metabolism. The complete 
exclusion criteria are listed in the Supplementary methods. 
Every author has received the approval of an Institutional Re-
view Board (IRB No. 2014-0087, KC13MFMV0619, 2013-09-
006, KUH1010517, 2013-08-0033, SMC2013-09-001, 2013-
2116, CUH-2013-09-008, CNUH2013-09-008, 2013-10-005, 
2013-0699-001) of each institution. All procedures followed 
were in accordance with the ethical standards of the responsible 
committee and with the Helsinki Declaration of 1964, as re-
vised in 2013. Informed consent was obtained from all patients.
Treatment
After a 2-week screening period, eligible patients were enrolled 
for treatment with insulin glargine and a stable dose of OADs 
for 24 weeks. In general, the doses and dosing frequency of 
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OADs were kept at the patient’s pre-study levels. However, a 
reduction in dose or discontinuation of the SU was allowed 
when hypoglycemia was predicted, at the discretion of the in-
vestigators. Insulin glargine was injected subcutaneously once 
daily between 8:00 PM and 10:00 PM, preferably at a fixed 
time. The recommended first dose was either 0.2 U/kg or 10 U. 
All subjects received appropriate education on the administra-
tion of insulin on at least two occasions prior to the first ad-
ministration.
The insulin dose was titrated at 3-day intervals using a treat-
to-target approach, based on the subject’s fasting self-moni-
tored blood glucose (SMBG) measurements. This dose was 
calculated according to the median of fasting SMBG results 
from the 3 previous consecutive days, with a target fasting 
SMBG level of 70 to 130 mg/dL. If fasting SMBG was in the 
range 130 to 160 mg/dL, the insulin dose was increased by 2 U, 
and for each 30 mg/dL above that range, a further 2 U (up to a 
maximum of 6 U) was added. If the fasting SMBG was in the 
range 50 to 70 mg/dL, a dose reduction of 4 U was recom-
mended. In cases of symptomatic hypoglycemia or a fasting 
SMBG level of ≤50 mg/dL, the dose was adjusted at the discre-
tion of the investigators. Subjects were advised to contact the 
investigators when their fasting SMBG levels were ≤50 or 
>250 mg/dL. They were also required to record the dose and 
timing of every injection, and investigators double-checked 
these records by inspecting the used and currently loaded in-
sulin cartridges. No specific counseling on dietary or lifestyle 
modification was provided for the study subjects. All laborato-
ry measurements were collected and analyzed centrally.
Effectiveness and safety assessments
HbA1c and fasting plasma glucose (FPG) were measured at 
weeks 12 and 24 of the study. The primary efficacy endpoint 
was the percentage of patients who met the HbA1c ≤7% at 
week 24. Secondary efficacy endpoints included the propor-
tion of subjects reaching the HbA1c target of ≤7% at week 12, 
the change in HbA1c, and the rate of change of HbA1c at 
weeks 12 and 24, compared with baseline. The proportions of 
subjects with HbA1c ≤6.5% at weeks 12 and 24, FPG, 2-hour 
postprandial plasma glucose (2h-PPG) at weeks 12 and 24, to-
tal daily insulin dose at week 24, mean fasting SMBG on 3 con-
secutive days during weeks 12 and 24, 7-point SMBG levels 
during weeks 4, 12, and 24, and BW changes were also assessed 
during the study period. 
The safety outcomes included adverse events (AEs) and hy-
poglycemic episodes. AEs were evaluated and coded according 
to MedDRA version 18.0 (McLean, VA, USA). Serious AE 
(SAE) was defined as one causing death or threatening life, or 
if one of the following conditions was met: (1) hospitalization 
or extension of hospital stay; (2) persistent or significant dis-
ability or incapacity; (3) congenital malformation or anomaly; 
or (4) any other significant medical event. 
Asymptomatic hypoglycemia was defined as a measured 
blood glucose level of ≤50 mg/dL without typical signs of hy-
poglycemia. Symptomatic hypoglycemia was defined as the 
presence of the typical clinical manifestations of hypoglycemia, 
with or without a measured blood glucose level of ≤70 mg/dL. 
Severe symptomatic hypoglycemia was defined by the pres-
ence of hypoglycemic symptoms that were severe enough to 
require help for recovery and a measured blood glucose level 
of ≤36 mg/dL, or by the presence of clinical symptoms that 
were rapidly alleviated following administration of an oral 
form of carbohydrate, intravenous glucose, or glucagon. Seri-
ous symptomatic hypoglycemia was classified as SAE and was 
defined if at least one of the following criteria was met: (1) loss 
of consciousness such that parenteral treatment by others was 
required; (2) seizure resulting from symptomatic hypoglyce-
mia; or (3) visit to an emergency department or hospitalization 
for the treatment of hypoglycemia.
Statistical analysis
To test the primary efficacy endpoint (i.e., percentage of pa-
tients who met the HbA1c ≤7% at 24 weeks), the required 
sample size for the trial was 108 patients to allow 90% power to 
detect the difference in the response rate at 24 weeks between a 
null hypothesis of 22% versus an alternative of 37%, using a 
two-sided alpha level of 0.05 with a withdrawal rate assumed 
to be approximately 15%. The proportion (%) and its 95% con-
fidence interval (CI) of subjects who met the target HbA1c of 
≤7% at the completion of the 24 week treatment period and 
the binomial test were used to test the significant difference of 
target rate of 22%. A between-group difference was compared 
using a chi-square test or Fisher’s exact test. 
The main analysis for effectiveness was performed on the 
full analysis set, in which all patients exposed to at least one 
dose of treatment and the HbA1c levels at 24 week were mea-
sured. The safety set consisted of all subjects who received at 
least one dose of treatment. Stratified analysis was conducted 
on combined treatment with SU. 
Continuous variables are summarized in observed values, 
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mean±standard deviation. Categorical variables are summa-
rized in observed values and proportion, and denominator was 
determined according to analysis group. All safety analysis was 
conducted in summary unless mentioned specifically, and all 
tests were performed at two-sided, 5% significance level. In all 
analyses on demographic information and basic information, 
primary and secondary parameters, and safety parameters, a 
subgroup analysis was conducted according to combined treat-
ment with SU, and comparative analysis using analysis of cova-
riance (ANCOVA) was made to see if there was difference be-
tween groups. Patients who were taking SU at screening but dis-
continued administering SU until one day prior to the initiation 
of the study drug (insulin glargine) were categorized as SU non-
users. Conversely, patients who have administered SU at screen-
ing period but discontinued SU after the day of study drug ad-
ministration remained in the SU combination group (SU users). 
Changes in 7-point SMBG measurements at weeks 12 and 24 
from baseline were evaluated by repeated measures analysis of 
variance (ANOVA). ANCOVA was used to analyze the be-
tween-group difference with baseline SMBG levels as covariates.
RESULTS
Patients and trial design
Demographic information and baseline characteristics of sub-
jects enrolled in this clinical trial are summarized in Table 1 
and the patient flow is illustrated in Fig. 1. Of 104 subjects, 87 
(83.7%) subjects were taking SU, and 17 (16.3%) subjects did 
not take SU during the study period. Three (17.7% of SU non-
users) subjects in whom SU was prescribed previously and 
then discontinued prior to study initiation were categorized as 
SU nonusers. Overall, there were more female (n=61, 58.65%) 
than male subjects (n=43, 41.35%), and this trend was similar-
ly observed among both SU users and nonusers (Table 1). The 
mean age of the study subjects was 58.0±10.0 years, and the 
mean duration of diabetes was 11.1±6.8 years (Table 1). The 
mean BMI of total subjects was 26.4±3.4 kg/m2, but the SU 
nonusers had higher BMI at baseline, and a shorter history of 
diabetes, compared with the SU users (Table 1). 
Effectiveness
Among the 104 subjects who were exposed to at least one dose 
of treatment, 33 subjects (31.7%) reached the HbA1c target of 
≤7.0% after 24 weeks (Table 2). The percentages of subjects 
who reached the HbA1c goal of ≤7% were significantly higher 
than 22%, disproving the null hypothesis of this study (P= 
0.028). In addition, the results were not significantly different 
between SU users (31.0%) and SU nonusers (35.3%; P=0.730) 
(Table 2). 
At week 12, 27.9% of the subjects had reached HbA1c ≤7.0% 
(95% CI, 19.5 to 37.5), and 27.6% SU users and 29.4% SU non-
users reached the target HbA1c without a statistically signifi-
Table 1. Demographic and baseline characteristics
Characteristic SU users (n=87) SU nonusers (n=17) Total (n=104) P value
Sex 0.988
   Male 36 (41.4) 7 (41.2) 43 (41.4)
   Female 51 (58.6) 10 (58.8) 61 (58.7)
Age, yr 58.6±10.1 54.7±9.4 58.0±10.0 0.142
BMI, kg/m2 26.1±3.4 27.7±3.1 26.4±3.4 0.044a
Body weight, kg 68.2±12.5 73.0±13.5 69.0±12.7 0.172
Duration of T2DM, yr 11.7±6.7 8.2±6.9 11.1±6.8 0.020a
Total metformin doses, mg/day 811.1±420.1 785.3±203.7 806.9±392.3 0.865
HbA1c, % 8.9±0.8 8.6±0.7 8.9±0.8 0.220
FPG, mg/dL 187.0±43.8 176.9±45.8 185.3±44.1 0.442
2-Hour PPG, mg/dL 298.7±70.2 271.4±54.1 294.2±68.3 0.831
Values are presented as number (%) or mean±standard deviation.
SU, sulfonylurea; BMI, body mass index; T2DM, type 2 diabetes mellitus; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; PPG, 
postprandial plasma glucose. 
aP<0.05: statistically significant.
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cant difference (P=1.000) (Table 2). Mean HbA1c significantly 
decreased by –1.3% ±0.9% at week 12 (P<0.001) and by 
–1.2%±0.9% at week 24 from baseline (P<0.001) (Table 2). 
There was no significant difference in the mean HbA1c changes 
between SU users and nonusers over the study period (Table 2).
At weeks 12 and week 24, the FPG levels significantly de-
creased by 59.9±49.5 and 56.0±49.8 mg/dL, respectively, from 
baseline, with no significant difference between the FPG levels 
of SU users and nonusers (Table 2). Likewise, 2h-PPG was also 
significantly decreased by 68.9±81.5 mg/dL at week 12 and 
68.6±77.1 mg/dL at week 24, and the use of SU did not signifi-
cantly affect the results (Table 2). 
The mean initial insulin dose after screening was 10.2±0.8 
U, and the mean daily insulin dose at week 24 was 18.6±12.6 
U (Supplementary Table 1). The mean daily insulin dose at 
week 24 was higher in non-SU users (i.e., 18.0±12.4 U in SU 
users vs. 21.8±13.5 U in SU nonusers), but this difference did 
not reach statistical significance (P=0.223) (Supplementary 
Table 1). The mean fasting SMBG measured on 3 consecutive 
days during weeks 12 and 24 significantly decreased from 
baseline by 50.6±43.6 and 51.1±41.7 mg/dL, respectively 
(P<0.001) (Supplementary Table 1), but the administration of 
SU as part of the regimen did not affect this parameter. 
The changes observed in the 7-point SMBG profile during 
the study period, which were measured immediately before 
breakfast, lunch, and dinner, 2 hours after each meal, and at 
bedtime, are illustrated in Fig. 2. The 7-point SMBG signifi-
cantly decreased by 4 weeks after treatment, and these levels 
remained similar until the 24 week of treatment (Fig. 2). 
The mean BW of the study subjects was 69.0±12.7 kg at 
baseline and 70.2±13.1 kg at 24 weeks, making the mean BW 
change 1.2±3.4 kg (P<0.001) (Table 2). Subgroup analysis re-
vealed that, over the 24 weeks of treatment, BW increased by 
1.5±2.5 kg among SU users whereas it decreased by 0.9±6.0 
kg in SU nonusers and that these differences were statistically 
significant (P=0.011) (Table 2).
Fig. 1. Patient flow. SU, sulfonylurea; HbA1c, glycosylated hemoglobin.
122 Screening
109 Enrollment
18 SU non-users
18 Safety analysis set
17 Full analysis set
91 SU users
90 Safety analysis set
87 Full analysis set
1 Not treated
3 Without HbA1c
after treatment
1 Without HbA1c
after treatment
13 Failure in screening
13  Violation of any of 
inclusion/exclusion criteria
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Safety endpoints
Of the 108 subjects in the safety analysis set, 112 hypoglycemic 
episodes in 36 subjects (33.33%) were reported (Supplementa-
ry Table 2). Among these episodes, 84 were of symptomatic 
daytime hypoglycemia, 22 were of symptomatic nocturnal hy-
poglycemia, and six were of asymptomatic hypoglycemia 
(Supplementary Table 2). Severe symptomatic hypoglycemia 
occurred in three episodes, consisting of one episode of severe 
daytime hypoglycemia, and two episodes of severe nocturnal 
hypoglycemia (Supplementary Table 2). All 112 hypoglycemic 
Table 2. Primary and secondary efficacy endpoints
Variable SU users (n=87)
SU nonusers 
(n=17)
Total 
(n=104)
Adjusted mean 
between-group difference 
(SU users vs. SU nonusers)
HbA1c, %
   Baseline 8.9±0.8 8.6±0.7 8.9±0.8
   Week 12 7.6±0.9 7.4±0.8 7.5±0.9
   Week 24 7.7±1.1 7.3±0.6 7.6±1.0
   Change from baseline to week 12 –1.3±0.9 –1.2±0.9 –1.3±0.9 0.05 (–0.37 to 0.47)
      P value <0.001 <0.001 <0.001 0.815
   Change from baseline to week 24 –1.2±1.0 –1.4±0.5 –1.2±0.9 0.29 (–0.18 to 0.75)
      P value <0.001 0.001 0.001 0.228
HbA1c ≤7% at week 12 24 (27.6) 5 (29.4) 29 (27.9) P=1.000
HbA1c ≤7% at week 24 27 (31.0) 6 (35.3) 33 (31.7) P=0.730
FPG, mg/dL
   Baseline 187.0±43.8 176.9±45.8 185.3±44.1
   Week 12 126.3±41.8 120.8±27.9 125.4±39.8
   Week 24 131.0±41.8 120.6±24.6 129.3±39.6
   Change from baseline to week 12 –60.7±50.9 –56.2±43.0 –59.9±49.5 2.8 (–17.4 to 23.0)
      P value <0.001 <0.001 <0.001 0.784
   Change from baseline to week 24 –55.0±50.9 –56.4±45.3 –56.0±49.8 7.8 (–12.3 to 27.9)
      P value <0.001 <0.001 <0.001 0.442
2-Hour PPG, mg/dL
   Baseline 298.7±70.2 271.4±54.1 294.2±68.3
   Week 12 228.5±78.6 213.6±59.2 226.1±75.9
   Week 24 226.3±75.7 219.5±42.8 225.3±71.5
   Change from baseline to week 12 –70.9±84.2 –57.9±66.1 –68.9±81.5 3.6 (–35.6 to 42.7)
      P value <0.001 0.003 <0.001 0.857
   Change from baseline to week 24 –71.7± 78.8 –51.9±67.3 –68.6±77.1 –3.9 (–40.2 to 32.4)
      P value <0.001 0.008 <0.001 0.831
Body weight, kg
   Baseline 68.2±12.5 73.0±13.5 69.0±12.7
   Week 24 69.8±13.2 72.0±12.9 70.2±13.1
   Changes 1.5±2.5 –0.9±6.0 1.2±3.4 2.4 (0.6 to 4.2)
      P value <0.001 0.296 <0.001 0.011
Values are presented as mean±standard deviation, least-squares mean difference (95% confidence interval), or number (%).
SU, sulfonylurea; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; PPG, postprandial plasma glucose. 
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episodes were fully recovered, and in 92 cases (82.1%), oral 
glucose administration was required for recovery. Among SU 
users, 97 hypoglycemic episodes were recorded in 30 subjects 
(33.3%), whereas 15 hypoglycemic episodes were reported in 
six subjects (33.3%) among SU nonusers. The incidence of hy-
poglycemic episodes did not differ between SU users and non-
users (P>0.05 for all categories of hypoglycemic episodes) 
(Supplementary Table 2). Any episode of serious symptomatic 
hypoglycemia was not reported throughout the study.
All AEs were mild or moderate; no severe AEs were record-
ed throughout the study period. Of 86 AEs reported, 71 
(82.6%) were mild, 15 (17.4%) were of moderate severity (Sup-
plementary Table 3), in which four AEs (4.7%) were evaluated 
as definitely, probably or possibly related to insulin glargine 
(Supplementary Table 4). Three cases (3.5%) resulted in per-
manent discontinuation of administration; administration of 
insulin glargine was temporarily discontinued in one case 
(1.5%) and insulin dose was reduced in one case (1.2%). Eight 
SAEs were reported, none of which were related to insulin 
glargine use. No statistically significant difference was found in 
AEs and adverse drug reactions between SU users and SU 
nonusers (Supplementary Table 3). 
DISCUSSION
Many patients with T2DM exhibit progressive β-cell dysfunc-
tion, meaning that it becomes increasingly difficult to achieve 
or maintain adequate glycemic control using only the currently 
available OADs [14]. Following the failure of OADs alone to 
maintain euglycemia, additive insulin administration can help 
improve glycemic control and prevent chronic diabetic com-
plications, especially if initiated early in the course of the dis-
ease [15]. Moreover, insulin administration can overcome glu-
cotoxicity and thereby preserve β-cell mass and function [16]. 
However, the risks of hypoglycemia and weight gain are major 
safety concerns that challenge clinicians when initiating insu-
lin therapy [6]; therefore, it is important to develop treatment 
regimens that minimize these side effects, while maximizing 
the benefit of insulins. 
A regimen consisting of basal insulin and OAD is simple 
and safe, and also incorporates the option of subsequent step-
wise intensification, once the patients accept the insulin injec-
tion [17]. In addition, the combination of basal insulin and a 
DPP-4 inhibitor is a logical therapeutic option, given their 
complementary effects [8]. However, to date, research into the 
effects of adding insulin to therapeutic regimens involving 
DPP-4 inhibitors±other OADs has been limited [8]. 
This study was designed to evaluate the effectiveness and 
safety of introducing insulin glargine to T2DM patients who 
had been failed to control dysglycemia with DPP-4 inhibitors+ 
metformin±SU. After 24 weeks of administering insulin 
glargine in addition to their pre-study OADs, 31.73% subjects 
had achieved their HbA1c goal of ≤7% (Table 2). Moreover, 
secondary outcome analysis revealed a significant reduction in 
FPG over the study period. Other secondary measures includ-
ing 2h-PPG, fasting SMBG for 3 consecutive days, and 7-point 
SMBG levels, were consistent with the primary endpoint, fur-
ther highlighting the effectiveness of adding insulin glargine to 
existing OAD-based treatment regimen. A subgroup analysis 
revealed that these findings stayed unchanged, regardless of 
Fig. 2. Mean 7-point self-monitored blood glucose (SMBG) profiles during the study period. 2h-PPG, 2-hour postprandial plas-
ma glucose. aP<0.05.
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the simultaneous administration of SU (Table 2 and Supple-
mentary Table 1). These results suggest that the addition of in-
sulin glargine is an effective add-on to such a regimen, alleviat-
ing hyperglycemia that was not controlled with DPP-4 inhibi-
tor and metformin±SU. In addition, cases of atherosclerosis 
and inflammation of the great toe were classified as definitely 
related AEs in this study (Supplementary Table 4). However, 
from a clinical perspective, these events might be more attrib-
utable to the underlying T2DM itself than the study drug ad-
ministration alone. Therefore, the addition of insulin glargine 
to DPP-4 inhibitor+metformin is considered relatively safe 
and tolerable, regardless of the concomitant use of SU (Supple-
mentary Tables 2 and 3).
Our study results are in line with previous studies, in which 
the safety and effectiveness of combining insulin with OADs 
including DPP-4 inhibitors were demonstrated. In a study of 
296 T2DM patients with inadequate glycemic control (mean 
HbA1c 8.4%) requiring high doses of basal insulin, addition of 
50 mg of vildagliptin twice daily resulted in a modest reduction 
of HbA1c (–0.5%±0.1%) compared with placebo (–0.3%± 
0.1%), with fewer hypoglycemic events [10]. Another study of 
390 longstanding T2DM patients on insulin therapy with the 
mean HbA1c level of 9.3%, showed that the addition of either 
12.5 or 25 mg/day of alogliptin significantly reduced HbA1c by 
–0.63% and –0.71%, respectively, compared with the placebo 
group [11]. During this study, the insulin doses used were un-
changed and the mean FPG was little affected by the treatment 
(i.e., 1.8 mg/dL increase with 12.5 mg and –10.8 mg/dL with 
25 mg alogliptin), suggesting that the reduction in HbA1c is 
primarily due to the control of postprandial hyperglycemia by 
alogliptin [11]. Although there have been no studies that have 
evaluated the effectiveness and safety of administering basal 
insulin alongside pre-study DPP-4 inhibitor/metformin, one 
study simultaneously initiated basal insulin and DPP-4 inhibi-
tor [18]. In this study of 222 insulin-free, T2DM patients 
whose hyperglycemia was inadequately controlled (mean 
HbA1c, 8.5%) by metformin±a second OAD, subjects were 
randomized to either an insulin determir+sitagliptin+metfor-
min arm or a sitagliptin+metformin±SU arm. After 26 weeks 
of treatment, patients who had initiated basal insulin with sita-
gliptin and metformin showed significantly higher reductions 
in HbA1c, FPG, and SMBG compared with those who had re-
ceived sitagliptin+metformin±SU [18]. In this study, no severe 
hypoglycemia was reported and AEs were less common in the 
group that was on insulin therapy [18]. Taken together with 
our findings, these results strongly support the effectiveness 
and safety of the insulin+DPP-4 inhibitor regimen for the 
treatment of patients with longstanding T2DM, as well as the 
hypothesis that the benefits of this combination might be de-
rived from their complementary effects.
In theory, the benefit of combining basal insulin and DPP-4 
inhibitors largely depends on the control of fasting glucose 
control by basal insulin and the correction of PPG excursions 
by DPP-4 inhibitors [8]. However, in the present study, 2h-
PPG levels were significantly reduced by 68.9±81.5 and 
68.6±77.1 mg/dL after 12 and 24 weeks of treatment with in-
sulin glargine, respectively, despite the continuation of pre-
study OADs (Table 2). This suggests that administration of 
basal insulin and a DPP-4 inhibitor together can have a syner-
gistic effect to lower postprandial hyperglycemia.
In the present study, the mean BW change was 1.15±3.38 
(Table 2), which is comparable to that from other studies 
which had evaluated the effect of insulin glargine-based com-
bination therapies [17-19]. In addition, because administration 
of insulin with SU has always raised a concern of severe hypo-
glycemia and additive weight gain [20], we ran subgroup anal-
yses according to the administration of SU. As a result, addi-
tion of insulin glargine in subjects taking SU did not signifi-
cantly increase the incidence of hypoglycemic episodes (Sup-
plementary Table 2). When insulin glargine was added, sub-
jects taking SU showed a mean weight gain of 1.53±2.51 kg 
(Table 2), whereas those without SU in their regimen showed a 
statistically non-significant weight loss of –0.86±5.95 kg (Table 
2) over the study period. Therefore, this difference (i.e., adjust-
ed mean between-group difference, 2.35 kg; P=0.011) (Table 
2) ascertains the weight neutral effect of adding insulin 
glargine in SU-free OAD combination, despite a slightly addi-
tive weight gain when combined with SU. Thus, our results 
provide further evidence to support the early addition of basal 
insulin to T2DM treatment regimens without significant fear 
of hypoglycemia and weight gain.
There are several strengths of the current study. First, it was 
the first study to demonstrate the effectiveness and safety of 
adding insulin glargine to pre-study DPP-4 inhibitor/metfor-
min regimens, thereby supporting the safety and effectiveness 
of adding basal insulin to treatment regimens based on DPP-4 
inhibitors and metformin±SU. Specifically, the major benefit 
of adding basal insulin to the combination of metformin and 
DPP-4 inhibitors were lack of severe hypoglycemia, regardless 
of the SU combination and its neutral or favorable effect on the 
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BW when SU is not combined. Second, because the pre-study 
OAD administration was not altered at the commencement of 
the study and was mostly maintained throughout the study pe-
riod, the results of this study should reflect the benefit of add-
ing insulin glargine to existing treatment regimens alone.
However, this study has several limitations. First, this was a 
single-arm clinical trial; hence, we could not compare the effect 
of adding insulin glargine to a placebo group, because the use 
of the latter would have been a major ethical violation. There-
fore, a few potential bias due to the nature of this study should 
be considered when interpreting our study results. For exam-
ple, the poor glycemic control at baseline of the subjects could 
possibly predispose towards a beneficial effect of the addition 
of insulin glargine over time. Because subjects’ dietary patterns 
or physical activity were not assessed throughout the study, we 
cannot rule out the possibility that the favorable study result is 
at least partly attributable to the lifestyle changes due to high 
motivation and treatment adherence associated with the initia-
tion of new insulin regimen. Second, because it was carried out 
in a single country, our results may not necessarily apply to 
people with other races and different backgrounds. However, 
given that a large multi-national clinical trial has already prov-
en the effectiveness and safety of insulin glargine [21], the 
principal findings of the present study are likely to be applica-
ble to populations from other backgrounds. Lastly, the sub-
group analyses between SU users and nonusers should be care-
fully interpreted as the number of SU nonusers was much 
smaller. In addition, because the SU nonusers exhibited higher 
BMI and shorter duration of diabetes compared to the SU us-
ers, the potential difference in endogenous insulin secretory 
capacity between the two groups should also be considered. 
In conclusion, this study was the first to demonstrate that the 
addition of insulin glargine to treatment regimens based on 
DPP-4 inhibitors and metformin for T2DM with inadequate 
glycemic control can lead to a significant improvement. The 
combination of insulin glargine alongside DPP-4 inhibitors 
and metformin was relatively safe and well-tolerable, resulting 
in minimal weight gain, and these beneficial effects remained 
significant regardless of the concomitant use of SU. This com-
bination is also simple to apply, making it a practical approach 
for patients, while also permitting stepwise intensification. 
Nevertheless, the effects of combining insulin with a treatment 
regimen based on DPP-4 inhibitors, should be further ex-
plored and confirmed in future larger scale clinical studies.  
SUPPLEMENTARY MATERIALS
Supplementary materials related to this article can be found 
online at https://doi.org/10.4093/dmj.2018.0092.
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Supplementary methods
Inclusion criteria 
Patients who meet any of the following criteria are eligible for study participation. 
1. Patients with type 2 diabetic mellitus (T2DM) ≥20 aged 
2.  Patients who are treated with dipeptidyl peptidase-4 inhibitor for at least 3 months before informed consent with metformin 
sulfonylurea inadequately controlled with glycosylated hemoglobin ≥7.5% before study
3. Patients who agreed with a written informed consent
Exclusion criteria 
1. Diabetes patients other than T2DM (e.g., T1DM, pancreatic disease, secondary diabetes)
2. History of continuous basal insulin treatment within 3 months before screening
3. History of diabetic acidosis (including keto-acidosis) within 1 year before screening
4. History of myocardial infarct, stroke or heart failure related admission within 3 months before screening
5. History of drug or alcoholic abuse within 6 months before screening
6. Weight change ≥5 kg within 3 months before screening
7. History of hypoglycemic unawareness
8.  Systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg regardless of taking anti-hypertensive, or un-
controlled hypertension
9.  Active malignant cancer, major systemic disease, clinically significant diabetic retinopathy, macular edema necessitating laser 
treatment, abnormal clinical finding from physical examination, lab analysis, electrocardiogram (EKG) or vital sign, which 
can be regarded as to prevent safe completion of clinical study or to make efficacy assessment difficult by investigator or co-in-
vestigator at screening
10.  Pregnant or lactating women
11.  Women of child bearing potential (pre-menopause or not surgically infertile within 3 months before screening) who match 
two conditions below
• Negative serum pregnancy test at screening
• Using medically proven effective contraceptive method 
12. Hypersensitivity to investigational drugs 
13. Lab finding at screening
• Abnormal liver function: alanine transaminase or aspartate transaminase >3 times of upper limit of normal range
• Renal insufficiency: men with serum Cr ≥1.5 mg/dL (≥133 µmol/L), women with serum Cr ≥1.4 mg/dL (≥124 µmol/L)
• Use of anti-obese drug within 3 months before screening
•  Has been using drugs that can influence glucose metabolism (systemic corticosteroid, thyroid hormone) within 3 months 
before screening or has possibility of using these drugs during the investigational period
• Has participated in clinical studies of any investigational drugs within 3 months before screening
14. Considered not physically or psychologically appropriate to participate in clinical study by investigator
15. Not willing to comply with scheduled visit, self-inject insulin, or self-monitor blood glucose level
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Supplementary Table 1. Other secondary and associated efficacy points 
Variable SU users (n=87)
SU nonusers 
(n=17)
Total 
(n=104)
Between-group difference 
SU users vs. SU nonusers
HbA1c ≤6.5% at week 12 9 (10.3) 1 (5.9) 10 (9.6) 1.000
HbA1c ≤6.5% at week 24 8 (9.2) 2 (11.8) 10 (9.6) 0.666
Daily insulin doses, IU
   Baseline 10.24±0.89 10.12±0.49 10.22±0.84 –4.06 (–10.63 to 2.51), P=0.223
   Week 24 18.02±12.35 21.82±13.47 18.64±12.55
3-Day mean FPG, mmol/L
   Baseline 9.28±2.59 9.26±2.30 9.28±2.53
   Week 12 6.50±1.71 6.80±1.28 6.55±1.65
   Week 24 6.56±1.55 6.58±1.29 6.57±1.50
Changes from baseline to week 12 –2.89±2.50 –2.46±2.01 –2.81±2.42    –0.37 (–1.18 to 0.43)
   P value <0.001 <0.001 <0.001 0.357
Changes from baseline to week 24 –2.87±2.34 –2.68±2.27 –2.84±2.32 –0.13 (0.79 to 0.53)
   P value <0.001 <0.001 <0.001 0.696
Values are presented as number (%), mean±standard deviation, or least-squares mean difference (95% confidence interval).
SU, sulfonylurea; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose.
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Supplementary Table 2. Incidence of hypoglycemic episodes
Variable
SU users SU nonusers Total
P value
N % E N % E N % E
Number of subjects in safety analysis set 90 18 108
   All hypoglycemic episodes 30 33.3 97 6 33.3 15 36 33.3 112 1.000
   Symptomatic daytime hypoglycemia 23 25.6 71 5 27.8 13 28 25.9 84 1.000
   Symptomatic nocturnal hypoglycemia 9 10 20 1 5.6 2 10 9.3 22 1.000
   Asymptomatic hypoglycemia 5 5.6 6 0 0 0 5 4.6 6 0.587
   Severe symptomatic daytime hypoglycemia 1 1.1 1 0 0 0 1 0.9 1 1.000
   Severe symptomatic nocturnal hypoglycemia 2 2.2 2 0 0 0 2 1.9 2 1.000
   Serious symptomatic daytime hypoglycemia 0 0 0 0 0 0 0 0 0 NA
   Serious symptomatic nocturnal hypoglycemia 0 0 0 0 0 0 0 0 0 NA
SU, sulfonylurea; N, number of subjects; E, number of hypoglycemic episodes; NA, not applicable.
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Supplementary Table 3. Incidence of adverse events
Variable SU users (n=90) SU nonusers (n=18) Total (n=108)
Number of AEs 67 19 86
Intensity
   Mild 53 (79.1) 18 (94.7) 71 (82.6)
   Moderate 14 (20.9) 1 (5.3) 15 (17.4)
   Severe 0 0 0 
Relationship
   Unknown 0 2 (10.5) 2 (2.3)
   Definitely not related 43 (64.2) 4 (21.1) 47 (54.7)
   Probably not related 21 (31.3) 12 (63.2) 33 (38.4)
   Possibly related 0 1 (5.3) 1 (1.2)
   Probably related 1 (1.5) 0 1 (1.2)
   Definitely related 2 (3.0) 0 2 (2.3)
Action taken
   None 63 (94.0) 18 (94.7) 81 (94.2)
   Dose increased 0 0 0 
   Dose reduced 1 (1.5) 0 1 (1.2)
   Dose temporarily withheld 1 (1.5) 0 1 (1.5)
   Dose permanently withheld 2 (3.0) 1 (5.3) 3 (3.5)
Outcome
   Recovered 52 (77.6) 19 (100) 71 (82.6)
      Recovered with sequale 3 (4.5)
      Not yet recovered 12 (17.9) 12 (14.0)
      Fatal 0 0 0 
   Treatment required
      Yes 36 (53.7) 6 (31.6) 42 (48.8)
      No 31 (46.3) 13 (68.4) 44 (51.2)
Values are presented as number (%).
SU, sulfonylurea; AE, adverse event.
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Supplementary Table 4. Details of adverse events 
No. Adverse event Seriousness Intensity Treatment required Relationship Action taken Outcome
1 Atherosclerosis No Mild Yes Definitely related None Not yet recovered
2 Itching sense No Mild No Probably related None Recovered
3 Skin itching No Moderate No Possibly related Dose permanently 
withheld
Recovered
4 Inflammation of 
the great toe
No Mild Yes Definitely related None Recovered
